XML 21 R6.htm IDEA: XBRL DOCUMENT v3.20.4
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)
$ in Thousands
 9 Months Ended
Dec. 26, 2020
Dec. 28, 2019
Cash Flows from Operating Activities:    
Net income $ 90,510 $ 58,902
Non-cash items:    
Depreciation and amortization 62,377 81,524
Impairment of assets 1,028 50,597
Share-based compensation expense 18,406 15,055
Deferred tax benefit (3,953) (4,747)
Provision for losses on accounts receivable and inventory 2,942 (2,246)
Gains on divestitures and sale of assets (32,613) (8,083)
Other non-cash operating activities 1,351 1,945
Change in operating assets and liabilities:    
Change in accounts receivable 18,588 13,807
Change in inventories (33,728) (68,251)
Change in prepaid income taxes 1,181 (273)
Change in other assets and other liabilities 2,687 (8,829)
Change in accounts payable and accrued expenses (21,518) (17,590)
Net cash provided by operating activities 107,258 111,811
Cash Flows from Investing Activities:    
Capital expenditures (25,408) (38,112)
Acquisition (16,606) 0
Proceeds from divestitures 44,587 9,808
Proceeds from sale of property, plant and equipment 1,085 16,263
Net cash provided by (used in) investing activities 3,658 (12,041)
Cash Flows from Financing Activities:    
Net (decrease) increase in short-term loans (60,000) 30,000
Repayment of term loan borrowings (13,125) (8,750)
Share repurchases 0 (175,000)
Proceeds from employee stock purchase plan 4,012 3,368
Proceeds from exercise of stock options 3,838 7,712
Other (32) 90
Net cash used in financing activities (65,307) (142,580)
Effect of exchange rates on cash and cash equivalents 6,082 (124)
Net Change in Cash and Cash Equivalents 51,691 (42,934)
Cash and Cash Equivalents at Beginning of Period 137,311 169,351
Cash and Cash Equivalents at End of Period 189,002 126,417
Supplemental Disclosures of Cash Flow Information:    
Interest paid 6,070 10,739
Income taxes paid 5,612 9,888
Transfers from inventory to fixed assets for placement of Haemonetics equipment $ 5,878 $ 10,705